NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Apr 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
11
Data completeness
6/8 — Strong
Priority Review
OXYCONTIN (oxycodone hydrochloride) by Purdue Pharma is receptor, although it can bind to other opioid receptors at higher doses. Approved for chronic pain, acute pain, osteoarthritis. First approved in 2010.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OxyContin (oxycodone hydrochloride) is an extended-release oral tablet indicated for the management of severe persistent pain in adults. It functions as a full mu-opioid receptor agonist with no ceiling effect for analgesia, achieving pain relief through binding to CNS opioid receptors in the brain and spinal cord. The drug is a cornerstone opioid analgesic in chronic pain management, though its use is subject to careful dose titration due to risks of respiratory and CNS depression.
$0.4BPart D
3.9 years to LOEMechanism of Action
receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited…
Indications (3)
Worked on OXYCONTIN at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.